サンプル依頼リスト カート
  • English
  • Korean
表紙：PEG化タンパク質の世界市場2023-2030
市場調査レポート
商品コード
1311906

PEG化タンパク質の世界市場2023-2030

Global PEGylated Proteins Market 2023-2030
出版日: | 発行: Orion Market Research | ページ情報: 英文 115 Pages | 納期: 2～3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
PEG化タンパク質の世界市場2023-2030
出版日: 2023年07月03日
発行: Orion Market Research
ページ情報: 英文 115 Pages
納期: 2～3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

PEG化タンパク質の世界市場は、予測期間中に1.8%のCAGRで成長すると予測されています。がん、腎臓病、関節リウマチなどの慢性疾患の有病率の増加は、それらの治療オプションに対する需要を生み出しました。米国がん協会（American Cancer Society 2022）のデータによると、2022年に米国で新たに診断されたがん患者は190万8030人と推定されています。さらに、同出典によると、すべてのがんの中で、消化器系がんは343,040症例を占め、乳がんは290,560症例を、次いで呼吸器系がんが2022年に254,850症例を新たに発症すると予想されています。さらに、UNAIDSの「Global HIV and AIDS Statistics, 2022 fact sheet」によると、2021年には世界で3,840万人がHIVとともに生活しています。このように、がん、HIV、結核などの慢性疾患や感染症の負担が世界的に増加していることから、医薬品開発の需要も増加することが予想され、これがタンパク質の研究を促進し、PEG化タンパク質市場を牽引することになります。

バイオテクノロジーや製薬会社によるPEG化タンパク質治療薬の分野での継続的な研究開発が、世界のPEG化タンパク質市場を牽引しています。例えば、2022年11月、Nektar Therapeuticsは2022年がん免疫療法学会（SITC）年次総会でNKTR-288の第1回前臨床データを発表しました。NKTR-288は、新規のポリエチレングリコール（PEG）-インターフェロン-γ（IFN-γ）結合体であり、IFN-γの基質への結合を修飾し、IFN-γシグナルの持続時間を最適化するように設計されています。IFN-γは細胞性抗原提示を誘導し、腫瘍抗原特異的細胞傷害性T細胞応答を増強するサイトカインであり、腫瘍学や感染症を含むいくつかの治療領域で応用が期待されています。

さらに2022年3月、抗体特性解析とタンパク質精製プロジェクトを促進・加速するために設立されたタンパク質科学部門であるFlow Eighteen38は、親会社であるCRO FairJourneyBiologics S.A.から、タンパク質生産と生物物理学的特性解析能力およびサービスに対して500万ユーロ（558万米ドル）の投資を受けたと発表しました。しかし、高い薬剤失敗率と薬剤回収は、世界のPEG化タンパク質市場の成長を抑制する可能性のある主な要因です。

セグメント別展望

消耗品サブセグメントがPEG化タンパク質の世界市場で大きなシェアを占める

製品/サービスの中では、消耗品サブセグメントが市場のかなりのシェアを占めると予想されます。消耗品サブセグメントはさらに、PEG化試薬とPEG化キットに二分されます。絶え間ない研究活動、製品開発、より優れた薬剤やドラッグデリバリー機構を処方する必要性は、キットや試薬のようなPEG化消耗品の継続的な消費に貢献し、その結果、高い収益を生むことになります。さらに、多くの製品を提供する大手企業の存在も、このセグメントの成長を後押ししています。

PEG化技術における利点と発展が、PEG化製品に対する需要の増加とともに、消耗品の大規模な採用を引き起こしています。研究開発や医薬品開発プログラムにおけるPEGの多用途な応用は、その利用を強化しています。さらに、様々なカスタムPEGコンジュゲーションサービスと製品提供企業は、意図した製品を提供するために消耗品を継続的に採用しています。PEG化タンパク質に対する需要の高まりと複数の製品プロバイダーの存在による消耗品の早い枯渇は、今後数年間の収益創出に貢献するでしょう。

地域別展望

北米がPEG化タンパク質の世界市場で主要シェアを占める

主要企業の存在と確立されたヘルスケアインフラの利用可能性は、この地域市場の高いシェアに貢献している主な要因のいくつかです。米国がん協会の推計によると、2022年に米国で新たに腎臓がんと診断される可能性があるのは79,000例で、そのうち男性が50,290例、女性が28,710例と予想されています。男女ともに悪性腫瘍のトップ10には腎臓がんが含まれています。男性の腎臓がん罹患リスクは生涯で約46人に1人（2.02％）。女性の場合、生涯リスクは約 80 人に 1 人 (1.03%) です。したがって、この地域における慢性疾患の有病率の増加は、市場の成長を促進すると考えられます。

さらに、政府の結束した取り組みや研究提携の増加も市場成長を促進すると予想される要因の一つです。例えば、2021年2月、Nautilus 社は特別目的買収会社（SPAC）であるArya III社と合併し、創薬や診断用途のタンパク質分析技術の開発作業を強化するために3億5,000万米ドルの初期投資を行っています。

目次

第1章 レポート概要

  • 業界の現状分析と成長ポテンシャルの展望
  • 調査方法とツール
  • 市場内訳
    • セグメント別
    • 地域別

第2章 市場概要と洞察

  • 調査範囲
  • アナリストの洞察と現在の市場動向
    • 主な調査結果
    • 推奨事項
    • 結論

第3章 競合情勢

  • 主要企業分析
  • Abcam Plc
    • 概要
    • 財務分析
    • SWOT分析
    • 最近の動向
  • Laysan Bio, Inc.
    • 会社概要
    • 財務分析
    • SWOT分析
    • 最近の動向
  • Thermo Fisher Scientific Inc.
    • 概要
    • 財務分析
    • SWOT分析
    • 最近の動向
  • 主要戦略分析

第4章 市場セグメンテーション

  • PEG化タンパク質の世界市場：製品/サービス別
    • 消耗品
    • サービス別
  • PEG化タンパク質の世界市場：エンドユーザー別
    • 製薬・バイオテクノロジー企業
    • 受託研究機関
    • 学術・研究機関
  • PEG化タンパク質の世界市場：用途別
    • がん
    • 自己免疫疾患
    • 肝炎
    • 多発性硬化症
    • 血友病
    • 消化器疾患
    • その他

第5章 地域分析

  • 北米
    • 米国
    • カナダ
  • 欧州
    • 英国
    • ドイツ
    • イタリア
    • スペイン
    • フランス
    • その他欧州
  • アジア太平洋
    • 中国
    • インド
    • 日本
    • 韓国
    • その他アジア太平洋地域
  • 世界のその他の地域

第6章 企業プロファイル

  • Abcam plc
  • Aurigene Pharmaceutical Services Ltd.
  • Celares GmbH
  • Creative PEGworks
  • Enzon Pharmaceuticals, Inc.
  • Laysan Bio, Inc.
  • Merck KGaA
  • NOF America Corp.
  • Profacgen
  • Thermo Fisher Scientific, Inc.
図表

LIST OF TABLES

  • 1. GLOBAL PEGYLATED PROTEINS MARKET BY PRODUCTS/SERVICES, 2022-2030 ($ MILLION)
  • 2. GLOBAL PEGYLATED PROTEINS CONSUMABLES MARKET BY REGION, 2022-2030 ($ MILLION)
  • 3. GLOBAL PEGYLATED PROTEINS SERVICES MARKET BY REGION, 2022-2030 ($ MILLION)
  • 4. GLOBAL PEGYLATED PROTEINS MARKET BY END-USER, 2022-2030 ($ MILLION)
  • 5. GLOBAL PEGYLATED PROTEINS FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES MARKET BY REGION, 2022-2030 ($ MILLION)
  • 6. GLOBAL PEGYLATED PROTEINS FOR CONTRACT RESEARCH ORGANIZATIONS MARKET BY REGION, 2022-2030 ($ MILLION)
  • 7. GLOBAL PEGYLATED PROTEINS FOR ACADEMIC & RESEARCH INSTITUTES MARKET BY REGION, 2022-2030 ($ MILLION)
  • 8. GLOBAL PEGYLATED PROTEINS MARKET BY APPLICATION, 2022-2030 ($ MILLION)
  • 9. GLOBAL PEGYLATED PROTEINS FOR CANCER TREATMENT MARKET BY REGION,2022-2030 ($ MILLION)
  • 10. GLOBAL PEGYLATED PROTEINS FOR AUTOIMMUNE DISEASES TREATMENT MARKET BY REGION,2022-2030 ($ MILLION)
  • 11. GLOBAL PEGYLATED PROTEINS FOR HEPATITIS TREATMENT MARKET BY REGION,2022-2030 ($ MILLION)
  • 12. GLOBAL PEGYLATED PROTEINS FOR MULTIPLE SCLEROSIS TREATMENT MARKET BY REGION,2022-2030 ($ MILLION)
  • 13. GLOBAL PEGYLATED PROTEINS FOR HEMOPHILIA TREATMENT MARKET BY REGION,2022-2030 ($ MILLION)
  • 14. GLOBAL PEGYLATED PROTEINS FOR GASTROINTESTINAL DISORDERS TREATMENT MARKET BY REGION,2022-2030 ($ MILLION)
  • 15. GLOBAL PEGYLATED PROTEINS FOR OTHER DISEASE TREATMENT MARKET BY REGION,2022-2030 ($ MILLION)
  • 16. GLOBAL PEGYLATED PROTEINS MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 17. NORTH AMERICAN PEGYLATED PROTEINS MARKET RESEARCH AND ANALYSIS BY PRODUCTS/SERVICES, 2022-2030 ($ MILLION)
  • 18. NORTH AMERICAN PEGYLATED PROTEINS MARKET RESEARCH AND ANALYSIS BY END-USER, 2022-2030 ($ MILLION)
  • 19. NORTH AMERICAN PEGYLATED PROTEINS MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2022-2030 ($ MILLION)
  • 20. NORTH AMERICAN PEGYLATED PROTEINS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
  • 21. EUROPEAN PEGYLATED PROTEINS MARKET RESEARCH AND ANALYSIS BY PRODUCTS/SERVICES, 2022-2030 ($ MILLION)
  • 22. EUROPEAN PEGYLATED PROTEINS MARKET RESEARCH AND ANALYSIS BY END-USER, 2022-2030 ($ MILLION)
  • 23. EUROPEAN PEGYLATED PROTEINS MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2022-2030 ($ MILLION)
  • 24. EUROPEAN PEGYLATED PROTEINS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
  • 25. ASIA-PACIFIC PEGYLATED PROTEINS MARKET RESEARCH AND ANALYSIS BY PRODUCTS/SERVICES, 2022-2030 ($ MILLION)
  • 26. ASIA-PACIFIC PEGYLATED PROTEINS MARKET RESEARCH AND ANALYSIS BY END-USER, 2022-2030 ($ MILLION)
  • 27. ASIA-PACIFIC PEGYLATED PROTEINS MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2022-2030 ($ MILLION)
  • 28. ASIA-PACIFIC PEGYLATED PROTEINS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
  • 29. REST OF THE WORLD PEGYLATED PROTEINS MARKET RESEARCH AND ANALYSIS BY PRODUCTS/SERVICES, 2022-2030 ($ MILLION)
  • 30. REST OF THE WORLD PEGYLATED PROTEINS MARKET RESEARCH AND ANALYSIS BY END-USER, 2022-2030 ($ MILLION)
  • 31. REST OF THE WORLD PEGYLATED PROTEINS MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2022-2030 ($ MILLION)

LIST OF FIGURES

  • 1. GLOBAL PEGYLATED PROTEINS MARKET SHARE BY PRODUCTS/SERVICES, 2022 VS 2030 (%)
  • 2. GLOBAL PEGYLATED PROTEINS CONSUMABLES MARKET BY REGION, 2022 VS 2030 (%)
  • 3. GLOBAL PEGYLATED PROTEINS SERVICES MARKET BY REGION, 2022 VS 2030 (%)
  • 4. GLOBAL PEGYLATED PROTEINS MARKET SHARE BY END-USER, 2022 VS 2030 (%)
  • 5. GLOBAL PEGYLATED PROTEINS FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES MARKET BY REGION, 2022 VS 2030 (%)
  • 6. GLOBAL PEGYLATED PROTEINS FOR CONTRACT RESEARCH ORGANIZATIONS MARKET BY REGION, 2022 VS 2030 (%)
  • 7. GLOBAL PEGYLATED PROTEINS BASED ACADEMIC & RESEARCH INSTITUTES MARKET BY REGION, 2022 VS 2030 (%)
  • 8. GLOBAL PEGYLATED PROTEINS MARKET SHARE BY APPLICATION, 2022 VS 2030 (%)
  • 9. GLOBAL PEGYLATED PROTEINS FOR CANCER MARKET BY REGION, 2022 VS 2030 (%)
  • 10. GLOBAL PEGYLATED PROTEINS FOR AUTOIMMUNE DISEASES MARKET BY REGION, 2022 VS 2030 (%)
  • 11. GLOBAL PEGYLATED PROTEINS FOR HEPATITIS MARKET BY REGION, 2022 VS 2030 (%)
  • 12. GLOBAL PEGYLATED PROTEINS FOR MULTIPLE SCLEROSIS MARKET BY REGION, 2022 VS 2030 (%)
  • 13. GLOBAL PEGYLATED PROTEINS FOR HEMOPHILIA MARKET BY REGION, 2022 VS 2030 (%)
  • 14. GLOBAL PEGYLATED PROTEINS FOR GASTROINTESTINAL DISORDERS MARKET BY REGION, 2022 VS 2030 (%)
  • 15. GLOBAL PEGYLATED PROTEINS FOR OTHER MARKET BY REGION, 2022 VS 2030 (%)
  • 16. GLOBAL PEGYLATED PROTEINS MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 17. US PEGYLATED PROTEINS MARKET SIZE, 2022-2030 ($ MILLION)
  • 18. CANADA MARKET PEGYLATED PROTEINS MARKET SIZE, 2022-2030 ($ MILLION)
  • 19. UK PEGYLATED PROTEINS MARKET SIZE, 2022-2030 ($ MILLION)
  • 20. GERMANY PEGYLATED PROTEINS MARKET SIZE, 2022-2030 ($ MILLION)
  • 21. SPAIN PEGYLATED PROTEINS MARKET SIZE, 2022-2030 ($ MILLION)
  • 22. FRANCE PEGYLATED PROTEINS MARKET SIZE, 2022-2030 ($ MILLION)
  • 23. ITALY PEGYLATED PROTEINS MARKET SIZE, 2022-2030 ($ MILLION)
  • 24. REST OF EUROPE PEGYLATED PROTEINS MARKET SIZE, 2022-2030 ($ MILLION)
  • 25. INDIA PEGYLATED PROTEINS MARKET SIZE, 2022-2030 ($ MILLION)
  • 26. CHINA PEGYLATED PROTEINS MARKET SIZE, 2022-2030 ($ MILLION)
  • 27. JAPAN PEGYLATED PROTEINS MARKET SIZE, 2022-2030 ($ MILLION)
  • 28. REST OFASIA-PACIFIC PEGYLATED PROTEINS MARKET SIZE, 2022-2030 ($ MILLION)
  • 29. REST OF WORLD PEGYLATED PROTEINS MARKET SIZE, 2022-2030 ($ MILLION)
目次
Product Code: OMR2027513

Title: Global PEGylated Proteins Market Size, Share & Trends Analysis Report Market by Products/ Services (Consumables and Services), by End-User (Pharmaceutical & Biotechnology Companies, Contract Research Organizations, and Academic & Research Institutes), and by Application (Cancer, Autoimmune Diseases, Hepatitis, Multiple Sclerosis, Hemophilia, Gastrointestinal Disorders, and Others) Forecast Period (2023-2030).

The global PEGylated proteins market is anticipated to grow at a considerable CAGR of 1.8% during the forecast period. The increasing prevalence of chronic disorders such as cancer, kidney diseases, and rheumatoid arthritis has created demand for their treatment options; which in turn driving the growth of the global PEGylated proteins market. According to the data from the American Cancer Society 2022, an estimated 1,908,030 new cancer cases were diagnosed in the US in 2022. Moreover, as per the same source, among all cancers, digestive system cancer accounts for 343,040 cases, breast cancer is expected to account for 290,560 new cancer cases, followed by respiratory system cancer, with 254,850 new cases in 2022. Additionally, as per the Global HIV and AIDS Statistics, 2022 fact sheet by UNAIDS, 38.4 million people globally were living with HIV in 2021. Thus, with the growing burden of chronic and infectious diseases such as cancer, HIV, tuberculosis, and others globally, the demand for developing medicine is also expected to increase, this will promote the research on protein, thus driving the PEGylated protein market.

The on-going R&D in the field of PEGylated proteins therapeutics by biotechnology and pharmaceutical companies' has driven the global PEGylated proteins market. For instance, in November 2022, Nektar Therapeutics presented 1st preclinical data for NKTR-288 at the 2022 Society for Immunotherapy of Cancer (SITC) Annual Meeting. NKTR-288 is a novel polyethylene glycol (PEG)-the conjugate of interferon-gamma (IFN-γ); it is designed to modify the binding of IFN-γ to its substrates and optimize the duration of IFN-γ signaling. IFN-γ is a cytokine that induces cellular antigen presentation and enhances tumor antigen-specific cytotoxic T-cell response and may have applications in several therapeutic areas, including oncology and infectious diseases.

Further in March 2022, Flow Eighteen38, a protein sciences division created to facilitate and accelerate antibody characterization and protein purification projects, announced a EUR 5 million (USD 5.58 million) investment into its protein production and biophysical characterization capabilities and services from its parent company, CRO FairJourneyBiologics S.A. In addition, there is rising adoption of protein-based drugs over non-protein-based drugs wherein PEGylation increases the circulation and half-life of the proteins, improving the efficacy. However, the high drug failure rates and drug recalls are the major factors that may restrain the growth of the global PEGylated proteins market.

Segmental Outlook

The global PEGylated proteins market is segmented based on product/ services, end-user, and application. Based on product/services, the market is bifurcated into consumables and services. Based on end-user, the market is sub-segmented into pharmaceutical & biotechnology companies, contract research organizations, and academic & research institutes. Based on application, the market is sub-segmented into cancer, autoimmune diseases, hepatitis, multiple sclerosis, hemophilia, gastrointestinal disorders, other.

Consumables Sub-Segment to Hold a Considerable Share of the Global PEGylated Proteins Market

Among the product/ services, the consumables sub-segment is expected to hold a considerable share of the market. The consumables sub-segment is further bifurcated into PEGlyation reagents and PEGylation kits. The never-ending research activities, product developments, and the need to formulate better drugs as well as drug-delivery mechanisms contribute to continuous consumption of PEGylating consumables, such as kits and reagents, and thus result in high revenue generation. Moreover, the presence of major players with numerous product offerings also drives segment growth.

The advantages and developments in PEGylation technology along with the increasing demand for PEGylated products have caused a huge adoption of consumables. The versatile application of PEG in research and drug development programs has bolstered its usage. Furthermore, various custom PEG conjugation services & product-providing companies are continuously employing consumables for delivering the intended products. The fast depletion of consumables due to an upswing in demand for PEGylated proteins along with the presence of multiple product providers will contribute to revenue generation in the years to come.

Regional outlooks

The global PEGylated proteins market is further segmented based on geography, including North America (the US and Canada), Europe (Italy, Spain, Germany, France, and others), Asia-Pacific (India, China, Japan, South Korea, and others), and the Rest of the World (the Middle East & Africa and Latin America). Among these, the Asia-Pacific region is anticipated to exhibit a healthy growth during forecast period.

North America to Hold a Major Share in the Global PEGylated Proteins Market

The presence of key players and availability of well established healthcare infrastructure are some of the key factors contributing to the high share of the regional market. According to the estimates of the American Cancer Society, in 2022, it was expected that 79,000 new instances of kidney cancer are likely to be diagnosed in the US in 2022, including 50,290 cases in males and 28,710 cases in women. The top 10 malignancies for both men and women include kidney cancer. Men have about a 1 in 46-lifetime risk of having kidney cancer (2.02%). For women, the lifetime risk is approximately 1 in 80. (1.03%). Thus, the growing prevalence of chronic diseases in the region is likely to propel the growth of the market.

Furthermore, the cohesive government initiatives and an increase in the number of research partnerships are some of the factors anticipated to drive market growth. For instance, in February 2021, Nautilus merged with Arya III, a special purpose acquisition company (SPAC), with an initial investment of $350 million to ramp up work developing its protein analysis technology for drug discovery and diagnostic applications.

Market Players Outlook

The major companies serving the global PEGylated proteins market include: Thermo Fisher Scientific, Inc., Abcam plc, Enzon Pharmaceuticals, Inc., Merck KGaA, and Celares GmbH among others. The market players are considerably contributing to the market growth by the adoption of various strategies, including collaborations, and new product launches, to stay competitive in the market. For instance, In July 2022, The European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) issued a favorable opinion, recommending the approval of doxorubicin hydrochloride (Celdoxome pegylated liposomal) for the treatment of metastatic breast cancer, advanced ovarian cancer, progressive multiple myeloma, and AIDS-related Kaposi's sarcoma.

The Report Covers:

  • Market value data analysis of 2022 and forecast to 2030.
  • Annualized market revenues ($ million) for each market segment.
  • Country-wise analysis of major geographical regions.
  • Key companies operating in the global PEGylated proteins market. Based on the availability of data, information related to new product launches, and relevant news is also available in the report.
  • Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
  • Analysis of market-entry and market expansion strategies.
  • Competitive strategies by identifying 'who-stands-where' in the market.

Table of Contents

1. Report Summary

  • Current Industry Analysis and Growth Potential Outlook
  • 1.1. Research Methods and Tools
  • 1.2. Market Breakdown
    • 1.2.1. By Segments
    • 1.2.2. By Region

2. Market Overview and Insights

  • 2.1. Scope of the Report
  • 2.2. Analyst Insight & Current Market Trends
    • 2.2.1. Key Findings
    • 2.2.2. Recommendations
    • 2.2.3. Conclusion

3. Competitive Landscape

  • 3.1. Key Company Analysis
  • 3.2. Abcam Plc
    • 3.2.1. Overview
    • 3.2.2. Financial Analysis
    • 3.2.3. SWOT Analysis
    • 3.2.4. Recent Developments
  • 3.3. Laysan Bio, Inc.
    • 3.3.1. Overview
    • 3.3.2. Financial Analysis
    • 3.3.3. SWOT Analysis
    • 3.3.4. Recent Developments
  • 3.4. Thermo Fisher Scientific Inc.
    • 3.4.1. Overview
    • 3.4.2. Financial Analysis
    • 3.4.3. SWOT Analysis
    • 3.4.4. Recent Developments
  • 3.5. Key Strategy Analysis

4. Market Segmentation

  • 4.1. Global PEGylated Proteins Market by Products/Services
    • 4.1.1. Consumables
    • 4.1.2. Services
  • 4.2. Global PEGylated Proteins Market by End-User
    • 4.2.1. Pharmaceutical & Biotechnology Companies
    • 4.2.2. Contract Research Organizations
    • 4.2.3. Academic & Research Institutes
  • 4.3. Global PEGylated Proteins Market by Application
    • 4.3.1. Cancer
    • 4.3.2. Autoimmune Diseases
    • 4.3.3. Hepatitis
    • 4.3.4. Multiple Sclerosis
    • 4.3.5. Hemophilia
    • 4.3.6. Gastrointestinal Disorders
    • 4.3.7. Others

5. Regional Analysis

  • 5.1. North America
    • 5.1.1. United States
    • 5.1.2. Canada
  • 5.2. Europe
    • 5.2.1. UK
    • 5.2.2. Germany
    • 5.2.3. Italy
    • 5.2.4. Spain
    • 5.2.5. France
    • 5.2.6. Rest of Europe
  • 5.3. Asia-Pacific
    • 5.3.1. China
    • 5.3.2. India
    • 5.3.3. Japan
    • 5.3.4. South Korea
    • 5.3.5. Rest of Asia-Pacific
  • 5.4. Rest of the World

6. Company Profiles

  • 6.1. Abcam plc
  • 6.2. Aurigene Pharmaceutical Services Ltd.
  • 6.3. Celares GmbH
  • 6.4. Creative PEGworks
  • 6.5. Enzon Pharmaceuticals, Inc.
  • 6.6. Laysan Bio, Inc.
  • 6.7. Merck KGaA
  • 6.8. NOF America Corp.
  • 6.9. Profacgen
  • 6.10. Thermo Fisher Scientific, Inc.